Therapeutic Solutions International (Therapeutic Solutions International) Cash And Cash Equivalents : $0.03 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Cash And Cash Equivalents?

Therapeutic Solutions International's quarterly cash and cash equivalents declined from Jun. 2023 ($0.12 Mil) to Sep. 2023 ($0.09 Mil) but then stayed the same from Sep. 2023 ($0.09 Mil) to Dec. 2023 ($0.03 Mil).

Therapeutic Solutions International's annual cash and cash equivalents declined from Dec. 2021 ($0.09 Mil) to Dec. 2022 ($0.02 Mil) but then increased from Dec. 2022 ($0.02 Mil) to Dec. 2023 ($0.03 Mil).

Therapeutic Solutions International Cash And Cash Equivalents Historical Data

The historical data trend for Therapeutic Solutions International's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Cash And Cash Equivalents Chart

Therapeutic Solutions International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.03

0.25

0.09

0.02

0.03

Therapeutic Solutions International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.02	0.02	0.12	0.09	0.03

Therapeutic Solutions International Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Therapeutic Solutions International (OTCPK:TSOI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Therapeutic Solutions International Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Wild Rose Lane, Elk City, ID, USA, 83525

Website

https://www.therapeuticsolutionsint.com

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

Executives

Thomas Ichim	director	211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg	officer: CFO	1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon	director, officer: Chairman, President, CEO	4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman	officer: VP, Training & Education	2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd	director, 10 percent owner	PO BOX 2145, RANCHO SANTA FE CA 92067